Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Thrombocytopenia-Associated Multiple Organ Failure and Acute Kidney Injury.

Nguyen TC, Cruz MA, Carcillo JA.

Crit Care Clin. 2015 Oct;31(4):661-74. doi: 10.1016/j.ccc.2015.06.004. Epub 2015 Aug 7. Review.

2.

The effect of shiga toxin on weibel-palade bodies in primary human endothelial cells.

Geelen J, van den Biggelaar M, Linssen P, van der Velden T, Mertens K, Monnens L.

Nephron Extra. 2014 Jul 8;4(2):101-7. doi: 10.1159/000363299. eCollection 2014 Jan.

3.

Proteolytic processing of von Willebrand factor by adamts13 and leukocyte proteases.

Lancellotti S, Basso M, De Cristofaro R.

Mediterr J Hematol Infect Dis. 2013 Sep 2;5(1):e2013058. doi: 10.4084/MJHID.2013.058. Review.

4.

Interaction of Shiga toxin with the A-domains and multimers of von Willebrand Factor.

Lo NC, Turner NA, Cruz MA, Moake J.

J Biol Chem. 2013 Nov 15;288(46):33118-23. doi: 10.1074/jbc.M113.487413. Epub 2013 Oct 4.

5.

The role of plasmapheresis in critical illness.

Nguyen TC, Kiss JE, Goldman JR, Carcillo JA.

Crit Care Clin. 2012 Jul;28(3):453-68, vii. doi: 10.1016/j.ccc.2012.04.009. Review.

6.

Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis.

Wong CS, Mooney JC, Brandt JR, Staples AO, Jelacic S, Boster DR, Watkins SL, Tarr PI.

Clin Infect Dis. 2012 Jul;55(1):33-41. doi: 10.1093/cid/cis299. Epub 2012 Mar 19.

7.

Shiga toxin pathogenesis: kidney complications and renal failure.

Obrig TG, Karpman D.

Curr Top Microbiol Immunol. 2012;357:105-36. doi: 10.1007/82_2011_172. Review.

8.

Early volume expansion during diarrhea and relative nephroprotection during subsequent hemolytic uremic syndrome.

Hickey CA, Beattie TJ, Cowieson J, Miyashita Y, Strife CF, Frem JC, Peterson JM, Butani L, Jones DP, Havens PL, Patel HP, Wong CS, Andreoli SP, Rothbaum RJ, Beck AM, Tarr PI.

Arch Pediatr Adolesc Med. 2011 Oct;165(10):884-9. doi: 10.1001/archpediatrics.2011.152. Epub 2011 Jul 22.

9.

Why Do We Need ADAMTS13?

Tsai HM.

Nihon Kessen Shiketsu Gakkai shi. 2005;16(1):54-69. No abstract available.

10.

Plasma exchange therapy for thrombotic microangiopathies.

Nguyen TC, Han YY.

Organogenesis. 2011 Jan-Mar;7(1):28-31. Epub 2011 Jan 1. Review.

11.

Pathophysiology of thrombotic thrombocytopenic purpura.

Tsai HM.

Int J Hematol. 2010 Jan;91(1):1-19. doi: 10.1007/s12185-009-0476-1. Review.

12.

The influence of riboflavin photochemistry on plasma coagulation factors.

Larrea L, Calabuig M, Roldán V, Rivera J, Tsai HM, Vicente V, Roig R.

Transfus Apher Sci. 2009 Dec;41(3):199-204. doi: 10.1016/j.transci.2009.09.006. Epub 2009 Sep 25.

13.

Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpura.

Tsai HM.

Kidney Int Suppl. 2009 Feb;(112):S11-4. doi: 10.1038/ki.2008.610. Review.

14.
15.

The kidney in thrombotic thrombocytopenic purpura.

Tsai HM.

Minerva Med. 2007 Dec;98(6):731-47. Review.

16.

Pathogenesis of thrombotic microangiopathies.

Zheng XL, Sadler JE.

Annu Rev Pathol. 2008;3:249-77. doi: 10.1146/annurev.pathmechdis.3.121806.154311. Review.

17.

Thrombotic thrombocytopenic purpura: a thrombotic disorder caused by ADAMTS13 deficiency.

Tsai HM.

Hematol Oncol Clin North Am. 2007 Aug;21(4):609-32, v. Review.

18.

Clinical surveillance of thrombotic microangiopathies in Scotland, 2003-2005.

Pollock KG, Young D, Beattie TJ, Todd WT.

Epidemiol Infect. 2008 Jan;136(1):115-21. Epub 2007 Mar 5.

19.

ADAMTS13 phenotype in plasma from normal individuals and patients with thrombotic thrombocytopenic purpura.

Manea M, Kristoffersson A, Tsai HM, Zhou W, Winqvist I, Oldaeus G, Billström R, Björk P, Holmberg L, Karpman D.

Eur J Pediatr. 2007 Mar;166(3):249-57. Epub 2006 Dec 24.

20.

ADAMTS13 and microvascular thrombosis.

Tsai HM.

Expert Rev Cardiovasc Ther. 2006 Nov;4(6):813-25. Review.

Supplemental Content

Support Center